• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

    11/13/24 4:15:05 PM ET
    $APLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APLT alert in real time by email
    SC 13G/A 1 tm2428198d1_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 6)

     

    Under the Securities Exchange Act of 1934

     

     

    APPLIED Therapeutics, Inc.

    (Name of Issuer)

     

    COMMON STOCK, $0.0001 PAR VALUE PER SHARE

    (Title of Class of Securities)

     

    03828A101

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 03828A101Page 2 of 8 Pages

     

    1.

    Name of Reporting Persons

     

    Alexandria Real Estate Equities, Inc.

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

     

    Maryland

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    12,094,054 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    12,559,054 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,559,054 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    10.3% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    CO

           

    (1)Consists of: (i) 5,390,077 shares of the Issuer’s common stock held by Alexandria Venture Investments, LLC (“AVI”); (ii) 1,500,000 shares of the Issuer’s common stock issuable upon exercise of pre-funded warrants (“Pre-Funded Warrants”) held directly by AVI that are currently exercisable; (iii) 2,950,000 shares of the Issuer’s common stock issuable upon exercise of common stock warrants (the “Common Stock Warrants” and, collectively with the Pre-Funded Warrants, the “Warrants”) held directly by AVI that are currently exercisable; (iv) 203,977 shares of the Issuer’s common stock held directly by Alexandria Equities No. 7, LLC (“AE7”); and (v) 2,050,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AE7 that are currently exercisable. Each of AVI and AE7 are indirect, wholly-owned subsidiaries of Alexandria Real Estate Equities, Inc. (“ARE”) and, accordingly, ARE may be deemed to share voting and dispositive power with AVI and AE7 with respect to the shares reported herein.

     

    (2)Consists of: (i) 5,855,077 shares of the Issuer’s common stock held by AVI; (ii) 1,500,000 shares of the Issuer’s common stock issuable upon exercise of Pre-Funded Warrants held directly by AVI that are currently exercisable; (iii) 2,950,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AVI that are currently exercisable; (iv) 203,977 shares of the Issuer’s common stock held directly by AE7; and (v) 2,050,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AE7 that are currently exercisable. Each of AVI and AE7 are indirect, wholly-owned subsidiaries of ARE and, accordingly, ARE may be deemed to share voting and dispositive power with AVI and AE7 with respect to the shares reported herein.

     

    (3)This percentage is calculated based upon 114,846,271 outstanding shares of the Issuer’s common stock as of August 6, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, as adjusted in accordance with Rule 13d-3 promulgated under the Securities Exchange Act, as amended.

     

     

     

     

    CUSIP No. 03828A101Page 3 of 8 Pages

     

    1.

    Name of Reporting Persons

     

    Alexandria Venture Investments, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    9,840,077 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    10,305,077 (2)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    10,305,077 (2)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    8.6% (3)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           

     

    (1)Consists of: (i) 5,390,077 shares of the Issuer’s common stock held by AVI; (ii) 1,500,000 shares of the Issuer’s common stock issuable upon exercise of Pre-Funded Warrants held directly by AVI that are currently exercisable; and (iii) 2,950,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AVI that are currently exercisable.

     

    (2)Consists of: (i) 5,855,077 shares of the Issuer’s common stock held by AVI; (ii) 1,500,000 shares of the Issuer’s common stock issuable upon exercise of Pre-Funded Warrants held directly by AVI that are currently exercisable; and (iii) 2,950,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AVI that are currently exercisable.

     

    (3)This percentage is calculated based upon 114,846,271 outstanding shares of the Issuer’s common stock as of August 6, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, as adjusted in accordance with Rule 13d-3 promulgated under the Securities Exchange Act, as amended.

     

     

     

     

    CUSIP No. 03828A101Page 4 of 8 Pages

     

    1.

    Name of Reporting Persons

     

    Alexandria Equities No. 7, LLC

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ¨

    (b) x

    3. SEC USE ONLY
    4.

    Citizenship or Place of Organization

     

    Delaware

    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:

    5.

    Sole Voting Power

     

    0

    6.

    Shared Voting Power

     

    2,253,977 (1)

    7.

    Sole Dispositive Power

     

    0

    8.

    Shared Dispositive Power

     

    2,253,977 (1)

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    2,253,977 (1)

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)  ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    1.9% (2)

    12.

    Type of Reporting Person (See Instructions)

     

    OO

           
    (1)Consists of: (i) 203,977 shares of the Issuer’s common stock held directly by AE7 and (ii) 2,050,000 shares of the Issuer’s common stock issuable upon exercise of Common Stock Warrants held directly by AE7 that are currently exercisable.

     

    (2)This percentage is calculated based upon 114,846,271 outstanding shares of the Issuer’s common stock as of August 6, 2024, as set forth in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024, as adjusted in accordance with Rule 13d-3 promulgated under the Securities Exchange Act, as amended.

     

     

     

     

    CUSIP No. 03828A101

    Page 5 of 8 Pages

     

    Item 1(a) Name of Issuer

     

    Applied Therapeutics, Inc.

     

    Item 1(b)Address of Issuer's Principal Executive Offices

     

    545 5th Avenue, Suite 1400

    New York, New York 10017

     

    Item 2(a)Name of Person Filing

     

    This Statement on Schedule 13G has been filed on behalf of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):

     

    (1) Alexandria Real Estate Equities, Inc.

    (2) Alexandria Venture Investments, LLC

    (3) Alexandria Equities No. 7, LLC

     

    Item 2(b)Address of Principal Business Office or, if none, Residence

     

    The address of each of the Reporting Persons is:

     

    26 North Euclid Avenue

    Pasadena, California 91101

     

    Item 2(c)Citizenship

     

    (1) Alexandria Real Estate Equities, Inc. is incorporated in the State of Maryland

    (2) Alexandria Venture Investments, LLC is organized in the State of Delaware

    (3) Alexandria Equities No. 7, LLC is organized in the State of Delaware

     

    Item 2(d) Title of Class of Securities

     

    Common stock, $0.0001 par value per share

     

    Item 2(e)CUSIP Number

     

    03828A101

     

    Item 3 

     

    Not applicable.

     

    Item 4Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1 as of November 13, 2024:

     

    (a) Amount beneficially owned: See Row 9 of pages 2, 3, and 4

     

    (b) Percent of class: See Row 11 of pages 2, 3, and 4

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote: See Row 5 of pages 2, 3, and 4

    (ii) Shared power to vote or to direct the vote: See Row 6 of pages 2, 3, and 4

    (iii) Sole power to dispose or to direct the disposition of: See Row 7 of pages 2, 3, and 4

    (iv) Shared power to dispose or to direct the disposition of: See Row 8 of pages 2, 3, and 4

     

     

     

     

    CUSIP No. 03828A101Page 6 of 8 Pages

     

    Item 5Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ¨

     

    Item 6Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

    Item 7Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

     

    Each of Alexandria Venture Investments, LLC and Alexandria Equities No. 7, LLC is the wholly owned subsidiary of Alexandria Real Estate Equities, Inc., which has the exclusive power to vote and dispose of shares directly owned by these subsidiaries.

     

    Item 8Identification and Classification of Members of the Group

     

    The Reporting Persons are filing this Schedule 13G jointly, but not as members of a group, and each expressly disclaims membership in a group.

     

    Item 9Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 03828A101Page 7 of 8 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 13, 2024

     

      ALEXANDRIA REAL ESTATE EQUITIES, INC.
       
      By: /s/ Marc E. Binda
      Name: Marc E. Binda
      Title: Chief Financial Officer and Treasurer
       
      ALEXANDRIA EQUITIES NO. 7, LLC
       
      By: ARE-Special Services, LLC, a Delaware limited liability company, managing member
       
        By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member
       
          By: ARE-QRS CORP., a Maryland corporation, general partner
       
            By: Alexandria Real Estate Equities, Inc., a Maryland corporation, sole shareholder
       
            By: /s/ Marc E. Binda
            Name: Marc E. Binda
            Title: Chief Financial Officer and Treasurer
       
      ALEXANDRIA VENTURE INVESTMENTS, LLC
       
      By: Alexandria Real Estate Equities, Inc., a Maryland corporation, managing member
       
      By: /s/ Marc E. Binda
      Name: Marc E. Binda
      Title: Chief Financial Officer and Treasurer

     

    EXHIBITS

     

    A:   Joint Filing Agreement

     

     

     

     

    CUSIP No. 03828A101Page 8 of 8 Pages

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Applied Therapeutics Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

     

    In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 13th of November, 2024.

     

      ALEXANDRIA REAL ESTATE EQUITIES, INC.
       
      By: /s/ Marc E. Binda
      Name: Marc E. Binda
      Title: Chief Financial Officer and Treasurer
       
      ALEXANDRIA EQUITIES NO. 7, LLC
       
      By: ARE-Special Services, LLC, a Delaware limited liability company, managing member
       
        By: ALEXANDRIA REAL ESTATE EQUITIES, L.P., a Delaware limited partnership, managing member
       
          By: ARE-QRS CORP., a Maryland corporation, general partner
       
            By: Alexandria Real Estate Equities, Inc., a Maryland corporation, sole shareholder
       
            By: /s/ Marc E. Binda
            Name: Marc E. Binda
            Title: Chief Financial Officer and Treasurer
       
      ALEXANDRIA VENTURE INVESTMENTS, LLC
       
      By: Alexandria Real Estate Equities, Inc., a Maryland corporation, managing member
       
      By: /s/ Marc E. Binda
      Name: Marc E. Binda
      Title: Chief Financial Officer and Treasurer

     

     

    Get the next $APLT alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $APLT

    DatePrice TargetRatingAnalyst
    12/23/2024Outperform → Mkt Perform
    William Blair
    12/2/2024$13.00 → $2.00Buy → Neutral
    UBS
    11/29/2024$12.00 → $4.00Outperform → Sector Perform
    RBC Capital Mkts
    7/31/2024Outperform
    William Blair
    3/26/2024$12.00Outperform
    RBC Capital Mkts
    2/22/2024$12.00Outperform
    Leerink Partners
    1/4/2022$44.00 → $7.00Overweight → Equal-Weight
    Barclays
    8/27/2021$10.00Neutral → Sell
    Goldman Sachs
    More analyst ratings

    $APLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Applied Therapeutics downgraded by William Blair

      William Blair downgraded Applied Therapeutics from Outperform to Mkt Perform

      12/23/24 7:22:04 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics downgraded by UBS with a new price target

      UBS downgraded Applied Therapeutics from Buy to Neutral and set a new price target of $2.00 from $13.00 previously

      12/2/24 8:14:03 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Applied Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $12.00 previously

      11/29/24 7:22:55 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    SEC Filings

    See more
    • Applied Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Applied Therapeutics, Inc. (0001697532) (Filer)

      6/17/25 4:07:43 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Applied Therapeutics, Inc. (0001697532) (Filer)

      6/12/25 6:01:27 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Applied Therapeutics Inc.

      SCHEDULE 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      5/15/25 4:30:28 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

      NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer. Dr. Baumgartner will serve as part of the Company's executive leadership team and will be responsible for leading Applied's global regulatory strategy. Dr. Baumgartner joins Applied as an accomplished global drug development leader with over 35 years of experience in senior regulatory, clinical development, and medical affairs roles. He has held a diverse set of leadership roles over the course of his career, notably

      3/19/25 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints Reena Thomas Colacot as Vice President and Head of Quality

      NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the appointment of Reena Thomas Colacot as Vice President and Head of Quality. Ms. Colacot joins Applied with over 25 years of quality leadership experience across the biopharmaceutical and medical device industries. In this newly created role, she will report directly to the executive leadership team and Executive Chairman, and will be responsible for overseeing all quality matters, including Good Manufacturing Practices, Good Laboratory Practices, and Good Clinical Practices. "We are pleased to

      1/21/25 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Financials

    Live finance-specific insights

    See more
    • Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

      Interim primary endpoint met; Statistically significant correlation of sorbitol with the CMT-FOM clinical outcome composite (p=0.05) Sustained, statistically significant reduction in sorbitol in govorestat-treated patients vs. placebo (p<0.001) Highly statistically significant effects on the CMT Health Index (CMT-HI) patient reported outcome measure (p=0.01), with benefit of govorestat on categories of lower limb function, mobility, fatigue, pain, sensory function, and upper limb function Company plans to request a pre-NDA meeting with the neurology division of the US FDA regarding potential approval based on current data Company to host investor conference call and webcast today at 8:3

      2/15/24 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Announces Clinical Benefit of Govorestat (AT-007) in ACTION-Galactosemia Kids Trial; Company Plans to Meet with FDA Regarding Potential NDA Submission

      Govorestat demonstrated consistent long-term clinical outcomes benefit across a range of functional measures in the ACTION-Galactosemia Kids trial, confirming prior biomarker dataGovorestat treatment improved activities of daily living, behavior, cognition, fine motor skills, adaptive skills and tremor vs. placeboCompany plans to request a pre-NDA meeting with the FDA as soon as possible to discuss a potential NDA submission in second half of 2023; plans to submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in mid-2023  NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company

      4/24/23 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

      The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and EuropeAT-007 reduced sorbitol by a mean of 52%, or approximately 16,000 ng/ml, over a 90 day period, which was highly statistically significant vs. placebo (p<0.001)Company to host conference call to discuss results at 8:30am Eastern NEW YORK, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medi

      2/16/23 7:00:00 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kanter Stacy J. bought $65,367 worth of shares (30,000 units at $2.18), increasing direct ownership by 91% to 63,000 units (SEC Form 4)

      4 - Applied Therapeutics Inc. (0001697532) (Issuer)

      12/5/23 7:03:09 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Funtleyder Leslie D. was granted 300,000 shares, increasing direct ownership by 47% to 937,121 units (SEC Form 4)

      4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      7/3/25 8:00:05 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Bailey Evan Prescott was granted 300,000 shares, increasing direct ownership by 55% to 841,669 units (SEC Form 4)

      4 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      6/17/25 4:09:41 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Bailey Evan Prescott claimed ownership of 541,669 shares (SEC Form 3)

      3 - Applied Therapeutics, Inc. (0001697532) (Issuer)

      6/17/25 4:08:49 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 5:47:55 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 4:50:26 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Applied Therapeutics Inc.

      SC 13G/A - Applied Therapeutics, Inc. (0001697532) (Subject)

      11/14/24 4:38:38 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Applied Therapeutics Announces Key Leadership Appointments

      Evan Bailey, MD, promoted to Chief Medical Officer, succeeding Riccardo Perfetti, MD, PhDDottie Caplan promoted to Executive Vice President, Patient Advocacy and Government Affairs NEW YORK, June 17, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced key appointments to its executive leadership team with the promotions of Evan Bailey, MD, to Chief Medical Officer (CMO), effective June 15, 2025, and Dottie Caplan to Executive Vice President (EVP), Patient Advocacy and Government Affairs. "We are pleased to appoint Evan as our next CMO, and Dottie as our EVP, Patien

      6/17/25 4:05:00 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

       Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through 24 months Statistically significant correlation between absolute reduction in sorbitol and change in 10MWRT and CMT-FOM Lower Limb domain at 12 months, though the primary endpoint of 10MWRT at 12 months was not statistically significant (the measure has since been removed from the CMT-FOM clinical outcomes assessment based upon the results of the ACT-CMT study*) Statistically significant improvement in CMT-HI and statistically significant correlation between percent change in sorbitol and change in CMT-HI at 12 months Treatment with govorestat in

      5/18/25 7:28:52 AM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Reports First Quarter 2025 Financial Results

      - Company to present full 12-month clinical data and new topline 18-month and 24-month data from INSPIRE registrational Phase 3 trial of govorestat in CMT-SORD Deficiency at the Peripheral Nerve Society 2025 Annual Meeting - Review of govorestat development programs for Classic Galactosemia and CMT-SORD Deficiency ongoing NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today reported financial results for the first quarter ended March 31, 2025. "We continue to focus on executing against our operational, regulatory and clinical

      5/13/25 5:00:00 PM ET
      $APLT
      Biotechnology: Pharmaceutical Preparations
      Health Care